Cut to the Bone: Amgen Faces Further Aranesp Decline Ahead of Denosumab
This article was originally published in RPM Report
Executive Summary
When it comes to Amgen, all eyes are on denosumab. That's as it should be: Amgen's future rides on the potential blockbuster. But investors shouldn't lose sight of Amgen's past and present: how the company manages the continued threats to Aranesp have important lessons for the biopharma sector as a whole-and for denosumab too.
You may also be interested in...
A Bad Day for Lucentis
On July 21, Roche reported strong first half sales of Lucentis. It was all downhill from there.
The Rebirth of A Niche Product: Three Silver Linings on the ESA REMS
The long-awaited Risk Evaluation & Mitigation Strategy for Aranesp and Procrit is here. For the oncology indication, it requires provider training program enrollment. It may not seem like the best outcome for Amgen and J&J, but there are some upsides.
The Slow Death of a Blockbuster
Bad news continues to mount for erythropoiesis-stimulating agents (ESAs), the flagship products of the biotechnology industry. Far from developing new markets, postmarket clinical trials by Amgen and J&J continue to point towards a much smaller appropriate patient population for Aranesp and Procrit.